Literature DB >> 29419438

Clonal evolution in the transition from cutaneous disease to acute leukemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm.

Eleni Ladikou1,2, Barbara Ottolini1,2, Nadia Nawaz1,2, Rebecca L Allchin1,2, Daniel Payne3, Hebah Ali4, Teresa Marafioti4, Jacqui Shaw1, Matthew J Ahearne5,2, Simon D Wagner5,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29419438      PMCID： PMC5927981          DOI： 10.3324/haematol.2017.171876

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.

Authors:  Fabrice Jardin; Philippe Ruminy; Francoise Parmentier; Xavier Troussard; Iona Vaida; Aspasia Stamatoullas; Stéphane Leprêtre; Dominique Penther; Anne B Duval; Jean-Michel Picquenot; Philippe Courville; Jean-Claude Capiod; Hervé Tilly; Christian Bastard; Jean P Marolleau
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

2.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.

Authors:  Cyril Quivoron; Lucile Couronné; Véronique Della Valle; Cécile K Lopez; Isabelle Plo; Orianne Wagner-Ballon; Marcio Do Cruzeiro; Francois Delhommeau; Bertrand Arnulf; Marc-Henri Stern; Lucy Godley; Paule Opolon; Hervé Tilly; Eric Solary; Yannis Duffourd; Philippe Dessen; Hélène Merle-Beral; Florence Nguyen-Khac; Michaëla Fontenay; William Vainchenker; Christian Bastard; Thomas Mercher; Olivier A Bernard
Journal:  Cancer Cell       Date:  2011-06-30       Impact factor: 31.743

3.  Landscape of TET2 mutations in acute myeloid leukemia.

Authors:  S Weissmann; T Alpermann; V Grossmann; A Kowarsch; N Nadarajah; C Eder; F Dicker; A Fasan; C Haferlach; T Haferlach; W Kern; S Schnittger; A Kohlmann
Journal:  Leukemia       Date:  2011-11-25       Impact factor: 11.528

4.  Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.

Authors:  J Menezes; F Acquadro; M Wiseman; G Gómez-López; R N Salgado; J G Talavera-Casañas; I Buño; J V Cervera; S Montes-Moreno; J M Hernández-Rivas; R Ayala; M J Calasanz; M J Larrayoz; L F Brichs; M Gonzalez-Vicent; D G Pisano; M A Piris; S Álvarez; J C Cigudosa
Journal:  Leukemia       Date:  2013-09-27       Impact factor: 11.528

Review 5.  CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells.

Authors:  Marco Herling; Dan Jones
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

6.  Clinical and biologic features of CD4(+)CD56(+) malignancies.

Authors:  Jean Feuillard; Marie-Christine Jacob; Françoise Valensi; Marc Maynadié; Rémy Gressin; Laurence Chaperot; Christine Arnoulet; Françoise Brignole-Baudouin; Bernard Drénou; Eliane Duchayne; Annie Falkenrodt; Richard Garand; Emanuelle Homolle; Bernard Husson; Emilienne Kuhlein; Geneviève Le Calvez; Danielle Sainty; Marie-France Sotto; Franck Trimoreau; Marie-Christine Béné
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

7.  Variegated RHOA mutations in adult T-cell leukemia/lymphoma.

Authors:  Yasunobu Nagata; Kenji Kontani; Terukazu Enami; Keisuke Kataoka; Ryohei Ishii; Yasushi Totoki; Tatsuki R Kataoka; Masahiro Hirata; Kazuhiro Aoki; Kazumi Nakano; Akira Kitanaka; Mamiko Sakata-Yanagimoto; Sachiko Egami; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Yusuke Shiozawa; Tetsuichi Yoshizato; Hiromichi Suzuki; Ayana Kon; Kenichi Yoshida; Yusuke Sato; Aiko Sato-Otsubo; Masashi Sanada; Wataru Munakata; Hiromi Nakamura; Natsuko Hama; Satoru Miyano; Osamu Nureki; Tatsuhiro Shibata; Hironori Haga; Kazuya Shimoda; Toshiaki Katada; Shigeru Chiba; Toshiki Watanabe; Seishi Ogawa
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

9.  Clonal architecture of chronic myelomonocytic leukemias.

Authors:  Raphaël Itzykson; Olivier Kosmider; Aline Renneville; Margot Morabito; Claude Preudhomme; Céline Berthon; Lionel Adès; Pierre Fenaux; Uwe Platzbecker; Olivier Gagey; Philippe Rameau; Guillaume Meurice; Cédric Oréar; François Delhommeau; Olivier A Bernard; Michaela Fontenay; William Vainchenker; Nathalie Droin; Eric Solary
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

10.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.

Authors:  Teresa Palomero; Lucile Couronné; Hossein Khiabanian; Mi-Yeon Kim; Alberto Ambesi-Impiombato; Arianne Perez-Garcia; Zachary Carpenter; Francesco Abate; Maddalena Allegretta; J Erika Haydu; Xiaoyu Jiang; Izidore S Lossos; Concha Nicolas; Milagros Balbin; Christian Bastard; Govind Bhagat; Miguel A Piris; Elias Campo; Olivier A Bernard; Raul Rabadan; Adolfo A Ferrando
Journal:  Nat Genet       Date:  2014-01-12       Impact factor: 41.307
View more
  2 in total

1.  Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.

Authors:  Xinmei Dang; Di Zhou; Lingjun Meng; Lintao Bi
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

Review 2.  Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells.

Authors:  Florian Renosi; Mary Callanan; Christine Lefebvre
Journal:  Cancers (Basel)       Date:  2022-08-26       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.